Literature DB >> 28401621

Mouse models of severe asthma: Understanding the mechanisms of steroid resistance, tissue remodelling and disease exacerbation.

Steven Maltby1,2, Hock L Tay1,2, Ming Yang1,2, Paul S Foster1,2.   

Abstract

Severe asthma has significant disease burden and results in high healthcare costs. While existing therapies are effective for the majority of asthma patients, treatments for individuals with severe asthma are often ineffective. Mouse models are useful to identify mechanisms underlying disease pathogenesis and for the preclinical assessment of new therapies. In fact, existing mouse models have contributed significantly to our understanding of allergic/eosinophilic phenotypes of asthma and facilitated the development of novel targeted therapies (e.g. anti-IL-5 and anti-IgE). These therapies are effective in relevant subsets of severe asthma patients. Unfortunately, non-allergic/non-eosinophilic asthma, steroid resistance and disease exacerbation remain areas of unmet clinical need. No mouse model encompasses all features of severe asthma. However, mouse models can provide insight into pathogenic pathways that are relevant to severe asthma. In this review, as examples, we highlight models relevant to understanding steroid resistance, chronic tissue remodelling and disease exacerbation. Although these models highlight the complexity of the immune pathways that may underlie severe asthma, they also provide insight into new potential therapeutic approaches.
© 2017 Asian Pacific Society of Respirology.

Entities:  

Keywords:  animal models; asthma; cell biology; cytokine; infection and inflammation

Mesh:

Substances:

Year:  2017        PMID: 28401621     DOI: 10.1111/resp.13052

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  16 in total

Review 1.  Obesity and severe asthma.

Authors:  Hiroki Tashiro; Stephanie A Shore
Journal:  Allergol Int       Date:  2018-12-01       Impact factor: 5.836

2.  Eosinophil persistence in vivo and sustained viability ex vivo in response to respiratory challenge with fungal allergens.

Authors:  W E Geslewitz; C M Percopo; H F Rosenberg
Journal:  Clin Exp Allergy       Date:  2017-11-22       Impact factor: 5.018

3.  Therapeutic efficacy of IL-17A neutralization with corticosteroid treatment in a model of antigen-driven mixed-granulocytic asthma.

Authors:  Katherine E Menson; Madeleine M Mank; Leah F Reed; Camille J Walton; Katherine E Van Der Vliet; Jennifer L Ather; David G Chapman; Bradford J Smith; Mercedes Rincon; Matthew E Poynter
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-12       Impact factor: 5.464

4.  The YAP/HIF-1α/miR-182/EGR2 axis is implicated in asthma severity through the control of Th17 cell differentiation.

Authors:  Jing Zhou; Ning Zhang; Wei Zhang; Caiju Lu; Fei Xu
Journal:  Cell Biosci       Date:  2021-05-12       Impact factor: 7.133

5.  Inhalations with Brine Solution from the 'Wieliczka' Salt Mine Diminish Airway Hyperreactivity and Inflammation in a Murine Model of Non-Atopic Asthma.

Authors:  Dominika Zając; Ewelina Russjan; Magdalena Kostrzon; Katarzyna Kaczyńska
Journal:  Int J Mol Sci       Date:  2020-07-07       Impact factor: 5.923

6.  The Applicability of Mouse Models to the Study of Human Disease.

Authors:  Kristina Rydell-Törmänen; Jill R Johnson
Journal:  Methods Mol Biol       Date:  2019

7.  Livin in synergy with Ras induces and sustains corticosteroid resistance in the airway mucosa.

Authors:  Jin-Mei Xue; Yun-Fang An; Li-Min Suo; Li-Hua Mo; Gui Yang; Xiang-Qian Luo; Da-Bo Liu; Chang-Qing Zhao; Ping-Chang Yang
Journal:  Int J Biol Sci       Date:  2021-05-13       Impact factor: 6.580

8.  An Alternative Dendritic Cell-Induced Murine Model of Asthma Exhibiting a Robust Th2/Th17-Skewed Response.

Authors:  Sang Chul Park; Hongmin Kim; Yeeun Bak; Dahee Shim; Kee Woong Kwon; Chang Hoon Kim; Joo Heon Yoon; Sung Jae Shin
Journal:  Allergy Asthma Immunol Res       Date:  2020-05       Impact factor: 5.764

9.  The AKT inhibitor MK2206 suppresses airway inflammation and the pro‑remodeling pathway in a TDI‑induced asthma mouse model.

Authors:  Haiyan Cui; Yuanxiong Cheng; Yi He; Weiying Cheng; Wenqu Zhao; Haijin Zhao; Fiona H Zhou; Liping Wang; Jianghui Dong; Shaoxi Cai
Journal:  Mol Med Rep       Date:  2020-08-21       Impact factor: 2.952

10.  Involvement of the epidermal growth factor receptor in IL-13-mediated corticosteroid-resistant airway inflammation.

Authors:  Elizabeth R Davies; Jeanne-Marie Perotin; Joanne F C Kelly; Ratko Djukanovic; Donna E Davies; Hans Michael Haitchi
Journal:  Clin Exp Allergy       Date:  2020-03-09       Impact factor: 5.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.